MOR103 Presentation - MorphoSys

More documents

Recommendations

Info

MOR103 – Mechanism of Action Inflammation & Synovitis Structural Damage – Bone Erosion ACR/ARHP 2012 – Washington DC – November 10-14, 2012 © MorphoSys AG
Anti-GM-CSF Monoclonal Antibody (MOR103) in RA Phase 1b/2a Randomized, Double-Blind, Placebo-Controlled Trial • Trial design – Randomized, double-blind, placebo-controlled, multicentre – 96 treated patients with active moderate RA (DAS28≤5.1) – Dose regimen: 0.3, 1.0 and 1.5 mg/kg weekly x 4 injected intravenously vs. placebo – Pooled placebo patients across 3 cohorts • Primary outcome measures – Adverse event rate and safety profile • Secondary outcome measures – DAS28, ACR core set measures and EULAR response criteria, MRI (synovitis) ACR/ARHP 2012 – Washington DC – November 10-14, 2012
Page 1 and 2: Abstract-Number: L11 First in Patie
Page 3: Disclosures • F. Behrens, M. Oste
Page 7 and 8: Study design 0.3 mg/kg MOR103 (n=25
Page 9 and 10: Baseline Disease Characteristics Ch
Page 11 and 12: Patient Disposition Placebo (n=27)
Page 13 and 14: ACR Response at Week 4 Percentage o
Page 15 and 16: EULAR Response at Week 4 Percentage
Page 17 and 18: Change of Synovitis by MRI Analysis
Page 19 and 20: Acknowledgements Investigators �
Page 21 and 22: Geographic Distribution of Patients
Page 23: DAS28 Response to Treatment MOR103

MOR103 Presentation - MorphoSys

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?